Abstract
The optimum graft-versus-host disease (GVHD) management in today's clinical practice remains controversial. There is an enormous heterogeneity among transplanters in their therapeutic decisions for each individual patient with GVHD. Existing guidelines do not always cover many unique clinical scenarios. Consequently, a significant number of allograft recipients fail either because of severe GVHD or relapse of underlying malignancy. Until more effective methods are available, tailoring the current GVHD management by modification of immunosuppressive therapy in each patient based on disease and transplant characteristics may decrease the mortality. The purpose of this review is to raise several questions among readers about GVHD management and generate new hypotheses, which may need to be tested in cooperative group studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A . The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996; 24: 71–79.
Uphoff DE . Graft versus host reaction modified by in vitro marrow-erythrocyte preincubation. Nature 1969; 222: 1089–1090.
Flowers ME, Kansu E, Sullivan KM . Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091–1112.
Ferrara JL, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.
Chao NJ, Chen BJ . Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006; 43: 32–41.
Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880–3887.
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.
Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006; 81: 818–825.
Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601–1605.
Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.
Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 1997; 3: 25–33.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH . Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.
Baron F, Beguin Y . Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 351–359.
Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414–421.
Lokhorst HM, Wu K, Verdonck LF, Latereer LL, van de Dork NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364.
Luft T, Moos M, Goldschmidt H, Ho AD, Gorner M . Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646–653.
Bleakley M, Riddell SR . Molecules and mechanisms of the graft-versus-leukemia effect. Nat Rev Cancer 2004; 4: 371–380.
Schmitz N, Barrett J . Optimizing engraftment – source and dose of stem cells. Semin Hematol 2002; 39: 3–14.
Barrett AJ, Rezvani K, Solomon S, Dickinso AM, Wang XN, Stark G et al. New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003; 350–371.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akpek, G. Titrating graft-versus-host disease: is it worth a try?. Bone Marrow Transplant 38, 653–656 (2006). https://doi.org/10.1038/sj.bmt.1705504
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705504